- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
High Dose of Opioids Post-surgery Tied to NSCLC Recurrence
Non-small cell lung cancer (NSCLC) patients who experienced disease recurrence half a decade after surgery received a significantly higher dose of opioids postoperatively, researchers said here.
Non-small cell lung cancer (NSCLC) patients who experienced disease recurrence half a decade after surgery received a significantly higher dose of opioids postoperatively, researchers said here.
In a retrospectve study among patients treated for early-stage NSCLC, recurrence occurred in 26 who received a mean dose of 232 mg of opioids in the 96 hours after surgery compared with 124 mg of opioids administered to the 73 patients in whom there was no recurrence in 5 years (P=0.020), reported Dermot Maher, MD,from Cedars-Sinai Medical Center in Los Angeles, and colleagues.
"A suggested mechanism is the opioid-induced inhibition of natural killer cell's ability to scavenge tumor cell emboli during the 'decisive period'," the authors wrote in a poster presentation at the annual scientific meeting of the American Pain Society.
Maher said that in the decisive period right after surgery, natural killer cells find and destroy cancer cells that might have spilled during the perioperative period. Maher said that opioids tend to inhibit the natural killer cell activity.
Read the complete report here: http://bit.ly/1upKsEU
Source: medpage Today
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Uniting to Support Patients With Cancer Beyond Treatment
November 17th 2024Kasey Bond, MPH, of Perlmutter Cancer Center at NYU Langone Health, speaks to why it’s vital to keep patients at the center of all strategic partnerships between academic institutions and community-based oncology practices.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Bridging Cancer Care Gaps and Overcoming Medical Mistrust
November 13th 2024In this clip from our interview with Oscar B. Lahoud, MD, cochair of our Institute for Value-Based Medicine® evening hosted with NYU Langone Health, he addressed medical mistrust in underrepresented communities.
Read More
How English- and Spanish-Preferring Patients With Cancer Decide on Emergency Care
November 13th 2024Care delivery innovations to help patients with cancer avoid emergency department visits are underused. The authors interviewed English- and Spanish-preferring patients at 2 diverse health systems to understand why.
Read More
